PT-141 (Bremelanotide)
Synthetic peptide studied in clinical and preclinical models for central mechanism of action and fda-approved efficacy
Last updated: March 1, 2026
- Compound
- PT-141 (Bremelanotide)
- Class
- Sexual Wellness peptide
- Summary
- Synthetic peptide studied in clinical and preclinical models for central mechanism of action, fda-approved efficacy, pde5 non-responder option.
- Mechanism
- Central-to-Peripheral Integration
- Research Status
- Approved
- Routes Studied
- Subcutaneous injection
- Evidence Level
- Clinically validated · Approved therapeutic
What Should You Know About PT-141 (Bremelanotide)?
- What is PT-141 (Bremelanotide)?
- PT-141 (Bremelanotide) is a synthetic peptide studied in clinical and preclinical models for central mechanism of action and fda-approved efficacy.
- Is PT-141 (Bremelanotide) clinically proven?
- PT-141 (Bremelanotide) is an approved therapeutic with established clinical evidence.
- What has PT-141 (Bremelanotide) been studied for?
- PT-141 (Bremelanotide) has been studied in clinical and preclinical settings of central mechanism of action, fda-approved efficacy, pde5 non-responder option and has received regulatory approval in at least one jurisdiction.
- Is PT-141 (Bremelanotide) approved?
- PT-141 (Bremelanotide) is an approved therapeutic in at least one jurisdiction. Regulatory status varies by country. Consult a local specialist for guidance.
What Is PT-141 (Bremelanotide)?
PT-141, also known as Bremelanotide, is a cyclic heptapeptide derived from the alpha-melanocyte-stimulating hormone (α-MSH) analogue Melanotan II. While Melanotan II was originally developed for tanning applications at the University of Arizona, researchers observed significant effects on sexual function during early trials, a serendipitous discovery that led to the development of PT-141 as a targeted compound for sexual dysfunction. In 2019, PT-141 received FDA approval under the brand name Vyleesi...
Evidence Summary
PT-141 (Bremelanotide) is an approved therapeutic with established clinical evidence and regulatory approval in at least one jurisdiction.
Evidence Breakdown
| Domain | Evidence Level |
|---|---|
| Central Mechanism of Action | Limited |
| FDA-Approved Efficacy | Limited |
| PDE5 Non-Responder Option | Limited |
| Holistic Sexual Response | Limited |
| Human clinical evidence | Established |
| Safety data | Established |
Editorial Position
PT-141 (Bremelanotide) is an approved therapeutic with established clinical evidence. As with any pharmaceutical compound, individual suitability should be discussed with a specialist.
Regulatory Status Snapshot
- Approved as a therapeutic drug in at least one jurisdiction
- Safety and efficacy established through regulatory review processes
Need help interpreting this evidence for your situation?
Talk to a SpecialistA deep research review for PT-141 (Bremelanotide) is not yet available. This compound profile is based on published peer-reviewed references listed below.
Browse all research reviewsWhat Has PT-141 (Bremelanotide) Been Studied For?
Research areas where PT-141 (Bremelanotide) has been investigated in published studies
-
Central Mechanism of Action PT-141 (Bremelanotide) has been studied in clinical and preclinical studies of central mechanism of action.
-
FDA-Approved Efficacy PT-141 (Bremelanotide) has been studied in clinical and preclinical studies of fda-approved efficacy.
-
PDE5 Non-Responder Option PT-141 (Bremelanotide) has been studied in clinical and preclinical studies of pde5 non-responder option.
-
Holistic Sexual Response PT-141 (Bremelanotide) has been studied in clinical and preclinical studies of holistic sexual response.
How Does PT-141 (Bremelanotide) Work?
These mechanisms have been established through clinical and preclinical research.
- 01 MC3R/MC4R Receptor Activation
- 02 Hypothalamic Signaling Cascade
- 03 Oxytocin & Dopamine Release
- 04 Central-to-Peripheral Integration
Not sure if PT-141 (Bremelanotide) is right for you?
A specialist can review the evidence, evaluate your medical context, and help you make an informed decision about PT-141 (Bremelanotide).
Community Reports (Anecdotal)
Experiences shared here are self-reported and do not represent clinical evidence.
Rate PT-141 (Bremelanotide)
How Is PT-141 (Bremelanotide) Administered?
PT-141 (Bremelanotide) is available via Subcutaneous injection, auto-injector pen, nasal spray. Appropriate use and protocol should be determined by a qualified specialist.
What Are the Specifications of PT-141 (Bremelanotide)?
Have Questions About PT-141 (Bremelanotide)?
PT-141 is a compound studied in clinical research that should only be used under qualified medical supervision. Cardiovascular screening is mandatory before initiating PT-141 due to its effects on blood pressure and heart rate.
The most commonly reported side effect is nausea, affecting approximately 40% of users in clinical trials. Transient blood pressure elevation, headache, flushing, and injection site reactions have also been reported. Most side effects are mild and self-limiting.
PT-141 is typically administered 45 minutes before anticipated sexual activity, which aligns with its central nervous system processing time. Effects generally last 6-12 hours after administration.
Ready to discuss PT-141 (Bremelanotide) with a specialist?
Get evidence-based guidance tailored to your health goals and medical context.
Book a Consultation Free initial consultation. No obligation.Reviewed by the Peptide Science Thailand Editorial Team.
Last reviewed: March 1, 2026